Currently, employing an anti‐TIM4 coadministration approach with anticancer vaccines enhances cytotoxic CD8+ T‐cell infiltration, contributing to tumor regression and yielding promising results in tumor therapy.[105]. Here, CD8A is linked to neoplasm.